tailieunhanh - Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: A case report

Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN